Replies to post #74577 on Cytodyn Inc (CYDY)

[All-Bidness]

The way I look at it is, if NP was going to sell why do it at these levels? He could make a deal and sell the company cheap and double/triple what he would've had if he sold now. I'm sure these is a company out there that would've paid $6/share to own the rights to leronlimab.

[justdafactss]

So why NOT ONE WORD from NP about any of this until the story was uncovered on the web?

All of this started on 4/30/2020.

It was said that he called it all a "lie" in an email correct?

[Blane]

Totally agree Saltz. It’s going to get interesting. Nail on the head!

[Grip it and Sip It]

Excellent point! And thanks for being the voice of reason! :)

Grip

[trader59]

It isn’t a distortion. Look at the gross proceeds from the sales of the stock. Even if the taxes were pertinent to what he did, the tax would be on the profits on the stock, his capital gain, not the gross. He sold $15.7M, the company got $6M, which means that Nader profited $9.7M. If taxes even matter, he gets about $6M post tax.

On the other hand, $6M to the company would have required dilution of only 1.85M shares at the weighted average of $3.25 had that been done instead of him cashing in his warrants. Instead, he dumped 2.5X's that into the float. He likely believes this price is good for him to sell his stock at.

His profit is the key, the gross of $9.7M to him. He sold his stock for a huge profit.

[MikefromWA]

Typical antibody manufacturing is very expensive and failure rates can easily exceed 10%. Coupled with the raw material costs, plant time and duration of a production campaign, the first few runs of a new product launch are very risky.

Some CMO structure their contracts such that payment is due between bulk production and final fill. This places the risk of complex production and timing on the CMO. Once the campaign is finished and released, the pressure shifts to payment which needs to occur to fully release the product in order to hit the schedule window at the final filling facility...

I am excited about this warrant activity because if CYDYs contract is structured in this way (I suspect it is) it means that we are closer to resupply than I thought... the potential implications are that the tricky steps are behind us and the fill could occur potentially in low risk weeks not high risk months.

Just my opinion...